Top

Journal of Endocrinological Investigation

Published in:

01-12-2016 | Original Article

Negative correlation between tumour size and cortisol/ACTH ratios in patients with Cushing’s disease harbouring microadenomas or macroadenomas

Authors: M. C. Machado, A. E. E. Alcantara, A. C. L. Pereira, V. A. S. Cescato, N. R. Castro Musolino, B. B. de Mendonça, M. D. Bronstein, M. C. B. V. Fragoso

Published in: Journal of Endocrinological Investigation | Issue 12/2016

Abstract

Purpose

Pituitary macroadenomas (MACs) represent 10–30 % of Cushing’s disease (CD) cases. The aim of this study was to report the clinical, laboratorial and imaging features and postsurgical outcomes of microadenoma (MIC) and MAC patients.

Methods

Retrospective study with 317 CD patients (median 32 years old, range 9–71 years) admitted between 1990 and 2014, 74 (23.3 %) of whom had MAC.

Results

Hirsutism, plethora facial, muscular weakness and muscular atrophy were more frequent in the MIC patients. Nephrolithiasis, osteopenia, hyperprolactinaemia and galactorrhoea were more prevalent in MAC patients. The morning serum cortisol (Fs), nocturnal salivary cortisol (NSC), nocturnal Fs (Fs 2400 h), low- and high-dose dexamethasone suppression test results and CRH and desmopressin test results were similar between the subgroups. MIC patients showed higher urinary cortisol at 24 h (UC), and MAC patients presented higher ACTH levels but lower Fs/ACTH, Fs 2400 h/ACTH, NSC/ACTH and UC/ACTH ratios. There were negative correlations of tumour size with Fs/ACTH, Fs 2400 h/ACTH, NSC/ACTH and UC/ACTH ratios. Overall, the postsurgical remission and recurrence rates were similar between MIC and MAC. However, patients in remission (MIC + MAC) showed smaller tumour diameters and a lower prevalence of invasion and extension on MRI.

Conclusions

Despite exhibiting higher plasma ACTH levels, CD patients with MAC presented lower cortisol/ACTH ratios than did patients with MIC, with a negative correlation between tumour size and cortisol/ACTH ratios. The overall postsurgical remission and recurrence rates were similar between MIC and MAC patients, with those with larger and/or invasive tumours showing a lower remission rate.

Katznelson L, Bogan JS, Trob JR et al (1998) Biochemical assessment of Cushing’s disease in patients with corticotroph macroadenomas. J Clin Endocrinol Metab 83(5):1619–1623PubMed

Blevins LS Jr, Christy JH, Khajavi M et al (1998) Outcomes of therapy for Cushing’s disease due to adrenocorticotropin-secreting pituitary macroadenomas. J Clin Endocrinol Metab 83(1):63–67PubMed

Woo YS, Isidori AM, Wat WZ et al (2005) Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas. J Clin Endocrinol Metab 90(8):4963–4969CrossRefPubMed

Mathioudakis N, Pendleton C, Quinones-Hinojosa A et al (2012) ACTH-secreting pituitary adenomas: size does not correlate with hormonal activity. Pituitary 15(4):526–532CrossRefPubMedPubMedCentral

Ikeda H, Yoshimoto T, Ogawa Y et al (1997) Clinico-pathological study of Cushing’s disease with large pituitary adenoma. Clin Endocrinol 46(6):669–679CrossRef

Selvais P, Donckier J, Buysschaert M et al (1998) Cushing’s disease: a comparison of pituitary corticotroph microadenomas and macroadenomas. Eur J Endocrinol 138(2):153–159CrossRefPubMed

Losa M, Barzaghi RLA, Mortini P et al (2000) Determination of the proliferation and apoptotic index in adrenocorticotropin-secreting pituitary tumors: comparison between micro- and macroadenomas. Am J Pathol 156(1):245–251CrossRefPubMedPubMedCentral

Fomekong E, Maiter D, Grandin C et al (2009) Outcome of transsphenoidal surgery for Cushing’s disease: a high remission rate in ACTH-secreting macroadenomas. Clin Neurol Neurosurg 111(5):442–449CrossRefPubMed

Hwang YC, Chung JH, Min YK et al (2009) Comparisons between macroadenomas and microadenomas in Cushing’s disease: characteristics of hormone secretion and clinical outcomes. J Korean Med Sci 24(1):46–51CrossRefPubMedPubMedCentral

10.

Chen JC, Amar AP, Choi S et al (2003) Transsphenoidal microsurgical treatment of Cushing disease: postoperative assessment of surgical efficacy by application of an overnight low-dose dexamethasone suppression test. J Neurosurg 98(5):967–973CrossRefPubMed

11.

Costenaro F, Rodrigues TC, Rollin GA et al (2014) Evaluation of Cushing’s disease remission after transsphenoidal surgery based on early serum cortisol dynamics. Clin Endocrinol (Oxf) 80(3):411–418CrossRef

12.

Hammer GD, Tyrrell JB, Lamborn KR et al (2004) Transsphenoidal microsurgery for Cushing’s disease: initial outcome and long-term results. J Clin Endocrinol Metab 89(12):6348–6357CrossRefPubMed

13.

Petersenn S, Beckers A, Ferone D et al (2015) Therapy of endocrine disease: outcomes in patients with Cushing’s disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. Eur J Endocrinol 172(6):R227–R239CrossRefPubMed

14.

Tirabassi G, Faloia E, Papa R et al (2010) Use of the desmopressin test in the differential diagnosis of pseudo-Cushing state from Cushing’s disease. J Clin Endocrinol Metab 95(3):1115–1122CrossRefPubMed

15.

Newell-Price J, Morris DG, Drake WM et al (2002) Optimal response criteria for the human CRH test in the differential diagnosis of ACTH-dependent Cushing’s syndrome. J Clin Endocrinol Metab 87(4):1640–1645PubMed

16.

Machado MC, de Sa SV, Domenice S et al (2007) The role of desmopressin in bilateral and simultaneous inferior petrosal sinus sampling for differential diagnosis of ACTH-dependent Cushing’s syndrome. Clin Endocrinol (Oxf) 66(1):136–142

17.

Patronas N, Bulakbasi N, Stratakis CA et al (2003) Spoiled gradient recalled acquisition in the steady state technique is superior to conventional postcontrast spin echo technique for magnetic resonance imaging detection of adrenocorticotropin-secreting pituitary tumors. J Clin Endocrinol Metab 88(4):1565–1569CrossRefPubMed

18.

Hofmann BM, Hlavac M, Martinez R et al (2008) Long-term results after microsurgery for Cushing disease: experience with 426 primary operations over 35 years. J Neurosurg 108(1):9–18CrossRefPubMed

19.

Bochicchio D, Losa M, Buchfelder M (1995) Factors influencing the immediate and late outcome of Cushing’s disease treated by transsphenoidal surgery: a retrospective study by the European Cushing’s Disease Survey Group. J Clin Endocrinol Metab 80(11):3114–3120PubMed

20.

De Tommasi C, Vance ML, Okonkwo DO et al (2005) Surgical management of adrenocorticotropic hormone-secreting macroadenomas: outcome and challenges in patients with Cushing’s disease or Nelson’s syndrome. Neurosurgery 103(5):825–830CrossRef

21.

Kakade HR, Kasaliwal R, Khadilkar KS et al (2014) Clinical, biochemical and imaging characteristics of Cushing’s macroadenomas and their long-term treatment outcome. Clin Endocrinol (Oxf) 81(3):336–342CrossRef

22.

Gibson S, Ray DW, Crosby SR et al (1996) Impaired processing of proopiomelanocortin in corticotroph macroadenomas. J Clin Endocrinol Metab 81(2):497–502PubMed

23.

Tateno T, Izumiyama H, Doi M et al (2007) Defective expression of prohormone convertase 1/3 in silent corticotroph adenoma. Endocr J 54(5):777–782CrossRefPubMed

24.

Ciric I, Zhao JC, Du H et al (2012) Transsphenoidal surgery for Cushing disease: experience with 136 patients. Neurosurgery 70(1):70–80CrossRefPubMedPubMedCentral

25.

Cannavò S, Almoto B, Dall’Asta C et al (2003) Long-term results of treatment in patients with ACTH-secreting pituitary macroadenomas. Eur J Endocrinol 149(3):195–200CrossRefPubMed

26.

Dimopoulou C, Schopohl J, Rachinger W et al (2013) Long-term remission and recurrence rates after first and second transsphenoidal surgery for Cushing’s disease: care reality in the Munich Metropolitan region. Eur J Endocrinol 170(2):283–292CrossRefPubMed

27.

Honegger J, Schmalisch K, Beuschlein F et al (2012) Contemporary microsurgical concept for the treatment of Cushing’s disease: endocrine outcome in 83 consecutive patients. Clin Endocrinol (Oxf) 76(4):560–567CrossRef

28.

Ammini AC, Bhattacharya S, Sahoo JP et al (2011) Cushing’s disease: results of treatment and factors affecting outcome. Hormones (Athens) 10(3):222–229CrossRef

29.

Rollin G, Ferreira NP, Czepielewski MA (2007) Prospective evaluation of transsphenoidal pituitary surgery in 108 patients with Cushing’s disease. Arq Bras Endocrinol Metabol 51(8):1355–1361CrossRefPubMed

30.

Shimon I, Ram Z, Cohen ZR et al (2002) Transsphenoidal surgery for Cushing’s disease: endocrinological follow-up monitoring of 82 patients. Neurosurgery 51(1):57–61CrossRefPubMed

31.

Alexandraki K, Kaltsas GA, Isidori AM et al (2013) Long-term remission and recurrence rates in Cushing’s disease: predictive factors in a single-centre study. Eur J Endocrinol 168(4):639–648CrossRefPubMed

32.

Dickerman RD, Oldfield EH (2002) Basis of persistent and recurrent Cushing disease: an analysis of findings at repeated pituitary surgery. J Neurosurg 97(6):1343–1349CrossRefPubMed

Title: Negative correlation between tumour size and cortisol/ACTH ratios in patients with Cushing’s disease harbouring microadenomas or macroadenomas
Authors: M. C. Machado
A. E. E. Alcantara
A. C. L. Pereira
V. A. S. Cescato
N. R. Castro Musolino
B. B. de Mendonça
M. D. Bronstein
M. C. B. V. Fragoso
Publication date: 01-12-2016
Publisher: Springer International Publishing
Published in: Journal of Endocrinological Investigation / Issue 12/2016
Electronic ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-016-0504-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2016

Adherence in children with growth hormone deficiency treated with r-hGH and the easypod™ device

Saint Wilgefortis: sudden hirsutism to prevent an unwanted marriage

Relationship of galectin-3 with obesity, IL-6, and CRP in women

Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas

Recommendations for treatment of hypothyroidism with levothyroxine and levotriiodothyronine: a 2016 position statement of the Italian Society of Endocrinology and the Italian Thyroid Association

The effect of glycaemic control in type 2 diabetic patients with subclinical hypothyroidism

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials